Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT02446925 Suspended - Clinical trials for Hepatocellular Carcinoma

Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study

Start date: May 2015
Phase: N/A
Study type: Interventional

The Surefire Infusion System is a novel catheter initially developed to prevent reflux of embolic material into non-target vascular territories. Further research has demonstrated improved penetration and distribution of embolic material into treated arterial territories. The purpose of this study is to compare Y-90 glass microsphere distribution and penetration into cancerous tissue within the liver between a standard endhole catheter and the Surefire Infusion System.

NCT ID: NCT02415036 Suspended - Clinical trials for Hepatocellular Carcinoma

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to the liver.

NCT ID: NCT02289300 Suspended - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients

Start date: January 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)

NCT ID: NCT02026362 Suspended - Clinical trials for Hepatocellular Carcinoma

Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

HCC DC CTL
Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.

NCT ID: NCT01690715 Suspended - Clinical trials for Hepatocellular Carcinoma

Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery

HSL2012-06
Start date: July 2012
Phase: N/A
Study type: Observational

A retrospective study based on analysis of medical records of patients with hepatocellular carcinoma treated at the Hospital Sírio-Libanês (Sao Paulo-Brazil) between 2001 and 2011 with diagnosis confirmed by imaging or histological specimen underwent surgical resection with curative intent. The study aims to determine the prognostic value of vascular complications related to cancer and to evaluate the survival rate of these patients, comparing the data with those reported in the literature.